Daily Cardiology Research Analysis
Across three impactful cardiology studies, imaging and hemodynamic biomarkers substantially improved risk stratification. Persistent microvascular obstruction on late cardiac MRI after STEMI predicted a markedly higher 5-year MACE, pulmonary arterial pressure trajectories before-to-after kidney transplantation closely tracked mortality, and elevated CRP independently forecasted heart failure and adverse cardiovascular outcomes after cardioversion for atrial fibrillation.
Summary
Across three impactful cardiology studies, imaging and hemodynamic biomarkers substantially improved risk stratification. Persistent microvascular obstruction on late cardiac MRI after STEMI predicted a markedly higher 5-year MACE, pulmonary arterial pressure trajectories before-to-after kidney transplantation closely tracked mortality, and elevated CRP independently forecasted heart failure and adverse cardiovascular outcomes after cardioversion for atrial fibrillation.
Research Themes
- Imaging biomarkers to refine post-MI risk stratification
- Hemodynamic trajectory modeling in transplant candidates
- Inflammation-based risk prediction in atrial fibrillation
Selected Articles
1. Long-term prognostic role of persistent microvascular obstruction determined by cardiac magnetic resonance for ST-segment elevation myocardial infarction.
In a multicenter prospective STEMI cohort with serial CMR at 1 week and 6 months, persistent microvascular obstruction (MVO) was present in 13.7% and conferred a markedly higher 5-year MACE risk (66%) compared with no MVO or transient MVO. Persistent MVO remained an independent predictor after adjustment (OR 3.91), with larger infarcts and lower LVEF throughout.
Impact: This study links a specific CMR phenotype in the chronic phase—persistent MVO—to long-term outcomes after STEMI, refining risk stratification beyond infarct size and early MVO status. It supports the clinical value of late CMR to identify high-risk patients.
Clinical Implications: Consider follow-up CMR at ~6 months post-STEMI to detect persistent MVO and intensify secondary prevention, surveillance, and enrollment into trials targeting microvascular injury. Persistent MVO may guide decisions on more aggressive remodeling therapies and closer follow-up.
Key Findings
- Persistent MVO at 6 months occurred in 13.66% (47/344) of STEMI patients.
- Five-year MACE was highest with persistent MVO (66.0%) versus transient MVO (27.6%) or no MVO (18.8%), P < .001.
- Persistent MVO independently predicted MACE after adjustment for other CMR variables (OR 3.912, 95% CI 1.904–8.037).
- Propensity-matched analysis confirmed higher MACE with persistent vs transient MVO (65.1% vs 37.2%, P = .010).
Methodological Strengths
- Prospective multicenter cohort with serial CMR at standardized time points.
- Five-year clinical follow-up with multivariable adjustment and propensity matching.
Limitations
- Observational design limits causal inference.
- Conducted at centers in China; generalizability and access to CMR may vary.
Future Directions: Test whether therapies targeting microvascular injury reduce persistent MVO and improve outcomes; evaluate routine late-phase CMR-guided management pathways after STEMI.
BACKGROUND: Microvascular occlusion (MVO) determined by cardiac magnetic resonance (CMR) exists both in acute phase and recovery period after myocardial infarction. This study aimed to examine the long-term prognosis predictive value of persistent MVO for ST-segment elevation myocardial infarction (STEMI). METHODS: A prospective cohort enrolled 344 patients with STEMI who received primary percutaneous coronary intervention and underwent CMR both in 5 to 7 days and 6 months after STEMI to determine if MVO had occurred. All patients were followed up for 5 years, and major adverse cardiovascular events (MACE) were recorded. RESULTS: This study included 344 STEMI patients with an average age of 57 years at 6 centers in China. A total of 192 (55.81%) patients with STEMI did not have MVO by CMR, and 105 (30.52%) patients showed transient MVO in acute phase of myocardial infarction and 47 (13.66%) patients showed persistent MVO at 6 months after infarction. The patients with persistent MVO had the largest infarct size and the lowest left ventricular ejection fraction both in 5 to 7 days and 6 months after infarction (all P < .001). Patients with persistent MVO showed a significantly higher incidence of 5-years MACE than those without MVO or with MVO in only 1 week (66.0% vs 18.8% and 27.6%, respectively; P < .001). Persistent MVO was an independent strong predictor of MACE after adjustment for other CMR variables (OR: 3.912, 95% CI: 1.904-8.037; P < .001). A propensity score-matched population comprised 43 patients with persistent MVO and 43 patients with transient MVO in only 1 week. The patients with persistent MVO had a higher incidence of MACE than those with transient MVO (65.1% [28/43] vs 37.2% [16/43]; P = .010). CONCLUSION: Persistent MVO by CMR at the chronic phase of STEMI provides useful prognostic information regarding long-term outcomes after primary percutaneous coronary intervention.
2. Longitudinal Pulmonary Arterial Pressure Trajectories and Clinical Outcome in Kidney Transplantation Patients.
In 631 KT patients, new-onset and persistent PH after transplantation were independently associated with higher mortality, while PH resolution was linked to the most favorable survival. Each 10 mm Hg increase in sPAP from pre- to post-KT raised mortality risk by 21%, and a 10 mm Hg decrease lowered risk by 17%, findings replicated in an external cohort.
Impact: This study operationalizes PAP trajectory as a prognostic biomarker around KT, demonstrating modifiable hemodynamics tightly track mortality and validating results across systems and modalities (echo and right heart catheterization).
Clinical Implications: Integrate PAP change (pre-to-post KT) into candidacy and post-KT risk assessment. Consider targeted PH management and optimization of hemodynamics pre/post KT, as decreases in sPAP are linked to lower mortality.
Key Findings
- New-PH and persistent-PH post-KT increased mortality risk vs no-PH (HR 1.51 and 1.37, respectively).
- Resolved PH had the most favorable survival (adjusted HR 0.73 vs no-PH).
- Each 10 mm Hg increase in sPAP from pre- to post-KT raised mortality by 21%; a 10 mm Hg decrease reduced mortality by 17%.
- Results were validated in an external, sex-balanced cohort using echocardiography and right heart catheterization.
Methodological Strengths
- Primary and external validation cohorts with complementary hemodynamic assessments (echo and RHC).
- Trajectory-based analysis linking continuous sPAP changes to mortality with robust adjustments.
Limitations
- Retrospective design with potential residual confounding.
- Primary cohort heavily male (VA system), possibly limiting generalizability; sPAP estimated by echocardiography.
Future Directions: Prospective trials to optimize PAP pre/post KT and test whether targeted PH therapy improving sPAP trajectories reduces mortality; integrate PAP change into KT selection algorithms.
BACKGROUND: Pulmonary hypertension (PH) is a high-risk finding in end-stage kidney disease (ESKD) and is independently associated with increased mortality. RESEARCH QUESTION: What is the relationship between pulmonary artery pressure (PAP) trajectories from before kidney transplantation (KT) to after KT, as well as the role of PH after KT? STUDY DESIGN AND METHODS: We retrospectively analyzed patients in the Veterans Affairs Healthcare System with PAP values both before KT and after KT using echocardiography. The primary exposure was all-cause mortality, stratified according to PH status (systolic PAP > 35 mm Hg) into four groups: No-PH (no PH pre-KT or post-KT), New-PH (no PH pre-KT but PH post-KT), Resolved-PH (PH pre-KT but no PH post-KT), and Persistent-PH (PH pre-KT and post-KT). Findings were validated in the sex-balanced Vanderbilt University Medical System using echocardiography and right heart catheterization. RESULTS: From 631 patients (aged 60 ± 6 years; 96% male) in the primary cohort, there were 231 (36.6%), 184 (29.2%), 133 (21.1%), and 83 (13.1%) patients in the Persistent-PH, Never-PH, Resolved-PH, and New-PH groups, respectively. New-PH and Persistent-PH were associated with a 51% (hazard ratio [HR], 1.51; 95% CI, 1.06-2.15; P = .023) and 37% (HR, 1.37; 95% CI, 1.03-1.82; P = .029) increase in age- and sex-adjusted mortality risk compared with No-PH. Of all groups, Resolved PH was associated with the most favorable survival rate (adjusted HR, 0.73; 95% CI, 0.51-1.05; P = .087, compared with No-PH). Longitudinal mortality risk increased continuously with ≥ 1 mm Hg PAP increase from pre-KT to post-KT. Overall, a 21% increase in mortality risk per 10 mm Hg increment increase in echocardiographic systolic PAP (sPAP) was observed from pre-KT to post-KT, adjusted for age, sex, and baseline sPAP (HR, 1.21; 95% CI, 1.11-1.31; P < .001); a 10 mm Hg sPAP decrease was associated with a 17% decrease in adjusted mortality risk (HR, 0.83; 95% CI, 0.76-0.90; P < .001). Results were reproducible in the validation cohort. INTERPRETATION: Our results indicate that in patients with ESKD referred for KT as well as hemodynamic assessment, outcome is strongly associated with PAP trajectory. These data suggest that PAP may be a novel biomarker for risk stratifying KT candidacy, supporting prospective ESKD studies investigating the role of PH in clinical decision-making.
3. Inflammation and risk of cardiovascular outcomes in patients with atrial fibrillation and flutter: A nationwide registry study.
In a nationwide cohort of 8,691 AF patients cardioverted for the first time, higher baseline CRP independently predicted incident HF (HR 1.06 per 1 mg/L; CRP >3 mg/L HR 1.78) over a median 719 days. Increased CRP also associated with ischemic heart disease and cardiovascular death after adjustments.
Impact: CRP is a low-cost, widely available biomarker; demonstrating independent prognostic value in AF after cardioversion supports its integration into risk stratification and surveillance strategies.
Clinical Implications: Consider measuring CRP during AF cardioversion pathways to identify patients warranting intensified HF surveillance and prevention. Elevated CRP may motivate closer follow-up, optimization of comorbidity management, and consideration of anti-inflammatory strategies in trials.
Key Findings
- Among 8,691 cardioverted AF patients, 8.2% developed HF over a median 719 days.
- CRP independently predicted incident HF (HR 1.06 per 1 mg/L increase; CRP >3 mg/L HR 1.78 vs ≤3 mg/L).
- Elevated CRP was also associated with ischemic heart disease and cardiovascular death after multivariable adjustment.
Methodological Strengths
- Large nationwide cohort with registry-linked outcomes and comprehensive adjustments.
- Clear exposure definition and clinically meaningful thresholds (CRP >3 mg/L).
Limitations
- Observational design; residual confounding and reverse causality cannot be excluded.
- CRP measured at baseline only; potential influence of intercurrent illnesses or variability over time.
Future Directions: Evaluate CRP-guided care pathways in AF and test anti-inflammatory interventions to reduce HF and CV events in randomized trials.
BACKGROUND: Atrial fibrillation (AF) is associated with the development of heart failure (HF). Inflammation is increasingly recognized as a driver for cardiovascular disease, but the impact of inflammation on the risk of cardiovascular outcomes in AF requires further investigation. OBJECTIVE: This study aimed to establish the prognostic value of C-reactive protein (CRP) in relation to CV outcomes in patients with AF treated with first-time direct current cardioversion. METHODS: A nationwide study of 8691 first-time direct current cardioverted patients with AF from 2011 to 2018 was conducted using the Danish National Health Registries for baseline comorbidities and prescribed medications. New-onset cardiovascular diagnoses were the primary outcomes, registered either at the outpatient clinic or upon admission. Incidence rates were reported, and multivariable adjusted Cox proportional hazard models presented the hazard ratios (HRs) for outcomes. RESULTS: During a median follow-up time of 719 days (interquartile range 328-1168 days), 568 (8.2%) developed HF. Higher CRP was associated with an increased risk of incident HF in univariable analysis (HR 1.07 per 1 mg/L increase in CRP, 95% confidence interval [CI] 1.05-1.08, P < .001) and multivariable analysis (HR 1.06, 95% CI 1.04-1.08, P < .001). Likewise, patients with CRP of > 3 mg/L had an increased risk of incident HF (HR 1.78, 95% CI 1.51-2.10, P < .001) compared with patients with CRP of ≤ 3 mg/L. CONCLUSION: In patients with AF, increased CRP was associated with an increased long-term risk of HF, ischemic heart disease, and CV death, even after multivariable adjustments. These results suggest that CRP may be a valuable risk marker in patients with AF.